Tranilast attenuates vascular hypertrophy, matrix accumulation and growth factor overexpression in experimental diabetes

Diabetes and Metabolism

Volumn 29, Issue 4 I, 2003, Pages 386-392

  Bonnet, F ^a,c   Cao, Z ^a   Cooper, M E ^a   Cox, A J ^b   Kelly, D J ^b   Gilbert, R E ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c LOUIS PRADEL HOSPITAL   (France)

Author keywords

Diabetes; Growth Factor; TGF ; Tranilast; Vasculature

Indexed keywords

COLLAGEN; EPIDERMAL GROWTH FACTOR; STREPTOZOCIN; TRANILAST; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL STRUCTURE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; DISEASE MODEL; DRUG EFFECT; DRUG MECHANISM; EXPERIMENTAL MODEL; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; IMMUNOHISTOCHEMISTRY; MALE; MAST CELL; MESENTERIC ARTERY; NONHUMAN; RAT; RNA EXTRACTION; STREPTOZOCIN DIABETES;

EID: 0141509964     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1262-3636(07)70049-6     Document Type: Article

References (34)

1. Kannel WB MD. Diabetes and cardiovascular disease: the Framingham study. JAMA, 1979, 241, 2035-8.
2. Clark CJ, Lee DA. Prevention and treatment of the complications of diabetes mellitus. N Engl J Med, 1995,332, 1210-7.
3. Simonsen U, Ehrnrooth E, Gerdes LU, et al. Functional properties in vitro of systemic small arteries from rabbits fed a cholesterol-rich diet for 12 weeks. Clin Sci, 1991, 80, 119-29.
4. Griffin SA, Brown WC, MacPherson F, et al. Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanism. Hypertension, 1991, 17, 626-35.
5. Rumble JR, Cooper ME, Soulis T, et al. Vascular hypertrophy in experimental diabetes: role of advanced glycation end products. J Clin Invest, 1997, 99, 1016-27.
6. Palmer AM, Gopaul N, Dhir S, Thomas CR, Poston L, Tribe RM. Endothelial dysfunction in streptozotocin-diabetic rats is not reversed by dietary probucol or simvastatin supplementation. Diabetologia, 1998, 41, 157-64.
7. Cooper ME, Rumble J, Komers R, Du HC, Jandeleit K, Chou ST. Diabetes-associated mesenteric vascular hypertrophy is attenuated by angiotensin-converting enzyme inhibition. Diabetes, 1994, 43, 1221-8.
8. Bray P, Agrotis A, Bobik A. Transforming growth factor-beta and receptor tyrosine kinase-activating growth factors negatively regulate collagen genes in smooth muscle of hypertensive rats. Hypertension, 1998, 31, 986-94.
9. Gilbert RE, Rumble JR, Cao ZM, et al. Endothelin receptor a antagonism ameliorates mast cell infiltration, vascular hypertrophy, and epidermal growth factor expression in experimental diabetes. Circ Res, 2000, 86, 158-65.
10. Sharma K, Jin Y, Guo J, Ziyadeh FN. Neutralization of TGF-β by anti-TGF-β antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes, 1996, 45, 522-30.
11. Gilbert RE, Cox A, McNally PG, et al. Increased epidermal growth factor expression in diabetes related kidney growth. Diabetologia, 1997, 40, 778-85.
12. Okuda M, Ishikawa T, Saito Y, Shimizu T, Baba S. A clinical evaluation of N-5′ with perennial-type allergic rhinitis-a test by the multiclinic, intergroup, double-blind comparative method. Ann Allergy, 1984, 53, 78-85.
13. Kosuga K, Tamai H, Ueda K, et al. Effectiveness of tranilast on restenosis after directional coronary atherectomy. Am Heart J, 1997, 134, 712-8.
14. Pinto YM, Pinto-Sietsma SJ, Philipp T, et al. Reduction in Left Ventricular Messenger RNA for Transforming Growth Factor beta(1) Attenuates Left Ventricular Fibrosis and Improves Survival Without Lowering Blood Pressure in the Hypertensive TGR(mRen2)27 Rat. Hypertension, 2000, 36, 747-54.
15. Ward MR, Sasahara T, Agrotis A, Dilley RJ, Jennings GL, Bobik A, Inhibitory effects of tranilast on expression of transforming growth factor-beta isoforms and receptors in injured arteries. Atherosclerosis, 1998, 137, 267-275.
16. Suzawa H, Kikuchi S, Arai N, Koda A. The mechanism involved in the inhibitory action of tranilast on collagen biosynthesis of keloid fibroblasts. Jpn J Pharmacol, 1992, 60, 91-6.
17. Ikeda H, Inao M, Fujiwara K. Inhibitory effect of tranilast on activation and transforming growth factor beta I expression in cultured rat stellate cells. Biochem Biophys Res Commun, 1996, 227, 322-7.
18. Bunag RD. Validation in awake rats of a tail-cuff method for measuring systolic pressure. J Appl Physiol, 1973, 34, 279-82.
19. Runible J, Komers R, Cooper M. Kinins/nitric oxide are involved in the anti-trophic effects of ACE inhibitors on diabetes associated mesenteric vascular hypertrophy. J Hypertens, 1996, 14, 601-607.
20. Masson P. Trichrome stainings and their preliminary technique. J Tech Methods, 1929, 2, 75-90.
21. Rumble JR, Cooper ME, Soulis T, et al. Vascular hypertrophy in experimental diabetes. Role of advanced glycation end products. J Clin Invest, 1997, 99, 1016-27.
22. Kranzhofer R, Schirmer J, Schomig A, et al. Suppression of neointimal thickening and smooth muscle cell proliferation after arterial injury in the rat by inhibitors of Na(+)- H+ exchange. Circ Res, 1993, 73, 264-8.
23. Kakinuma Y, Kawamura T, Bills T, Yoshioka T, Ichikawa I, Fogo A. Blood pressure-independent effect of angiotensin inhibition on vascular lesions of chronic renal future. Kidney Int, 1992, 42, 46-55.
24. Lehr HA, Mankoff DA, Corwin D, Santeusanio G, Gown AM. Application of photoshop-based image analysis to quantification of hormone receptor expression in breast cancer. J Histochem Cytochem, 1997, 45, 1559-65.
25. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem, 1987, 162, 156-9.
26. Martell M, Gomez J, Esteban JI, et al. J. High-throughput real-time reverse transcription-PCR quantitation of hepatitis C virus RNA. J Clin Microbiol, 1999, 37, 327-32.
27. Wasty F, Alavi MZ, Moore S. Distribution of glycosaminoglycans in the intima of human aortas: changes in atherosclerosis and diabetes mellitus. Diabetologia, 1993, 36, 316-22.
28. Dybdahl H, Ledet T. Diabetic macroangiopathy. Quantitative histopathological studies of the extramural coronary arteries from type 2 (non-insulin-dependent) diabetic patients. Diabetologia, 1987, 30, 882-6.
29. Williamson JR, Tilton RG, Chang K, Kilo C. Basement membrane abnormalities in diabetes mellitus: relationship to clinical microangiopathy. Diabetes Metab Rev, 1988, 4, 339-70.
30. Gibbons GH, Dzau VJ. The emerging concept of vascular remodeling. N Engl J Med, 1994, 330, 1431-8.
31. Cooper ME, Rumble J, Komers R, Du HC, Jandeleit K, Chou ST. Diabetes-associated mesenteric vascular hypertrophy is attenuated by angiotensin-converting enzyme inhibition. Diabetes, 1994, 43, 1221-8.
32. Holmes D, Fitzgerald P, Goldberg S, et al. The PRESTO (Prevention of restenosis with tranilast and its outcomes) protocol: a double-blind, placebo-controlled trial. Am Heart J, 2000, 139, 23-31.
33. Rumble JR, Gilbert RE, Cox A, Wu L, Cooper ME. Angiotensin converting enzyme inhibition reduces the expression of transforming growth factor-beta(1) and type IV collagen in diabetic vasculopathy. J Hypertens, 1998, 16, 1603-9.
34. Nie L, Mogami H, Kanzaki M, Shibata H, Kojima I. Blockade of DNA synthesis induced by platelet-derived growth factor by tranilast, an inhibitor of calcium entry, in vascular smooth muscle cells. Mol Pharmacol, 1996, 50, 763-9.